Loperamide 2mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

loperamide 2mg tablets

alliance healthcare (distribution) ltd - loperamide hydrochloride - oral tablet - 2mg

Loperamide 2mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

loperamide 2mg tablets

morningside healthcare ltd - loperamide hydrochloride - oral tablet - 2mg

LOPERAMIDE HCL tablet United States - English - NLM (National Library of Medicine)

loperamide hcl tablet

l.n.k. international, inc. - loperamide hydrochloride (unii: 77ti35393c) (loperamide - unii:6x9oc3h4ii) - loperamide hydrochloride 2 mg

LOPERAMIDE HYDROCHLORIDE capsule United States - English - NLM (National Library of Medicine)

loperamide hydrochloride capsule

ncs healthcare of ky, inc dba vangard labs - loperamide hydrochloride (unii: 77ti35393c) (loperamide - unii:6x9oc3h4ii) - loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies. loperamide hydrochloride capsules are contraindicated in patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. loperamide hydrochloride is contraindicated in patients with abdominal pain in the absence of diarrhea. loperamide hydrochloride is not recommended in infants below 24 months of age. loperamide hydrochloride should not be used as the primary therapy: - in patients with acute dysentery, which is characterized by blood in stools and high fever, - in patients with acute ulcerative colitis, - in patients with bacterial enterocolitis caused by invasive organisms including salmonella, shigella, and campylobacter, - in patients with pseudomembranous colitis associated with the u